Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Siirt Training and Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07084753CT.gov Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy | — | Not Yet Recruiting | — | — | — |
NCT05026125CT.gov Quality Assessment of Orotracheal Intubation Without Neuromuscular Blocking Agents in Obese Patients | — | Completed | — | — | — |
NCT06714981CT.gov Hemodynamics Stability During Opioid Free Anesthesia for Patients with Obesity | — | Completed | — | — | — |
NCT04260659CT.gov Opioid Free vs Opioid Based Anesthesia for Laparoscopic Sleeve Gastrectomy | — | Completed | — | — | — |
NCT03756961CT.gov Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery | — | Recruiting | — | — | — |
NCT03029715CT.gov Anaesthesia for Laparoscopic Sleeve Gastrectomy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Obesity Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ramifentanyl (this asset) | Siirt Training and Research Hospital | Approved | B · 58 |
| vi-0521 | VIVUS LLC | P4 | BBB |
| Tirzepatide | Royal North Shore Hospital | P4 | BBB |
| asc30 | Ascletis Pharma (China) Co., Limited | P2 | BBB |
| Phentermine | Russell McCulloh, MD | P4 | BBB |
| Survodutide | Boehringer Ingelheim | P3 | BBB |
| Deoxycholic Acid | University of California, San Diego | P4 | BBB |
| Efsubaglutide Alfa | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BBB |
| Cagrilintide | Novo Nordisk A/S | P3 | BBB |
+42 more in the Obesity Disorder cohort
Other indications for Ramifentanyl
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cardiovascular Disorder | — | P4 | BBB · 73 |
| Morbid Obesity | — | P4 | BBB · 73 |
| Chronic Pain Syndrome | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ramifentanyl in Obesity Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ramifentanyl-obesity-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →